Abstract
Background
Infective endocarditis (IE) is diagnosed in 7–8% of streptococcal bloodstream infections (BSIs), yet it is unclear when to perform transthoracic (TTE) and transoesophageal echocardiography (TOE) according to different streptococcal species. The aim of this sub-study was to propose a flowchart for the use of echocardiography in streptococcal BSIs.
Methods
In a population-based setup, we investigated all patients admitted with streptococcal BSIs and crosslinked data with nationwide registries to identify comorbidities and concomitant hospitalization with IE. Streptococcal species were divided in four groups based on the crude risk of being diagnosed with IE (low-risk < 3%, moderate-risk 3–10%, high-risk 10–30% and very high-risk > 30%). Based on number of positive blood culture (BC) bottles and IE risk factors (prosthetic valve, previous IE, native valve disease, and cardiac device), we further stratified cases according to probability of concomitant IE diagnosis to create a flowchart suggesting TTE plus TOE (IE > 10%), TTE (IE 3–10%), or “wait & see” (IE < 3%).
Results
We included 6393 cases with streptococcal BSIs (mean age 68.1 years [SD 16.2], 52.8% men). BSIs with low-risk streptococci (S. pneumoniae, S. pyogenes, S. intermedius) are not initially recommended echocardiography, unless they have ≥3 positive BC bottles and an IE risk factor. Moderate-risk streptococci (S. agalactiae, S. anginosus, S. constellatus, S. dysgalactiae, S. salivarius, S. thermophilus) are guided to “wait & see” strategy if they neither have a risk factor nor ≥3 positive BC bottles, while a TTE is recommended if they have either ≥3 positive BC bottles or a risk factor. Further, a TTE and TOE are recommended if they present with both. High-risk streptococci (S. mitis/oralis, S. parasanguinis, G. adiacens) are directed to a TTE if they neither have a risk factor nor ≥3 positive BC bottles, but to TTE and TOE if they have either ≥3 positive BC bottles or a risk factor. Very high-risk streptococci (S. gordonii, S. gallolyticus, S. mutans, S. sanguinis) are guided directly to TTE and TOE due to a high baseline IE prevalence.
Conclusion
In addition to the clinical picture, this flowchart based on streptococcal species, number of positive blood culture bottles, and risk factors, can help guide the use of echocardiography in streptococcal bloodstream infections. Since echocardiography results are not available the findings should be confirmed prospectively with the use of systematic echocardiography.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12879-021-06391-2.
Keywords: Infective endocarditis, Streptococcal species, Bloodstream infection, Echocardiography
Background
Streptococci are one of the leading causes of infective endocarditis (IE), yet there is uncertainty when to screen for IE in patients with streptococcal bloodstream infections (BSIs) [1–4]. A nationwide registry study found an IE prevalence of 16.7% in Enterococcus faecalis (E. faecalis), 10.1% in Staphylococcus aureus (S. aureus), and 7.3% in streptococcal bloodstream infections (BSIs), leading the authors to suggest that screening for IE in these patients seems reasonable [5]. In both S. aureus and E. faecalis BSIs a more extensive use of echocardiography has been recommended based on echocardiographic screening studies finding a IE prevalence around 15–25% [6–8].
In a recent large cohort study, we showed that different streptococcal species had markedly different IE prevalence, ranging from 1 to 2% in S. pneumoniae and S. pyogenes to almost 50% in S. gordonii and S. mutans [9]. These findings support the fact that not all streptococcal species carry the same risk of IE and therefore it is highly relevant to consider if the work-up should be differentiated between patients infected with different streptococcal species. The current European and American guidelines on IE are not specifying anything regarding the prevalence of IE nor the differentiation of work-up in patients with BSIs due to different streptococcal species [10, 11]. Furthermore, risk factors for IE in patients with a streptococcal BSI have been sparsely investigated. Sunnerhagen et al. created a score to guide the use of echocardiography in non-β-haemolytic streptococcal BSIs based on different risk factors [12]. However, the study was limited by low numbers, not differentiating between when to perform transthoracic (TTE) or transoesophageal echocardiography (TOE) and failing to include all the different streptococcal species.
In the present study our aim was to propose a flowchart for the use of echocardiography in patients with streptococcal BSIs based on retrospective data of IE prevalence according to streptococcal species and IE risk factors.
Methods
Study population, data sources and case definitions
This is a sub-study to a population-based study including adult patients with monospecies streptococcal BSIs admitted from January 1, 2008 to December 31, 2017 in the Capital Region of Denmark (1.5 million people) [9]. The full method has been described in detail in the main study. In addition to the main study exclusion of cases with unavailable species identification, the current sub-study also excluded rare species accounting for < 0.5% of BSIs. Using Danish nationwide registries [13, 14] we identified IE cases with hospital admissions with primary and secondary ICD-10 codes (I33, I38 and I39.8) and IE was considered associated to the streptococcal BSI, if the positive blood cultures occurred during the IE admission or up to 30 days prior. Since detailed patient chart data including data on echocardiograms are not available in the registries the estimated IE prevalence is based on the assumption that when the hospital doctors diagnose a patient with IE the patient actually has IE and in the same way, when a patient is not diagnosed with IE it is because the patient does not have IE. To reduce the number of false positive IE diagnoses, we required IE cases to have a hospital admission of minimum 14 days unless they died during the first 14 days of admission because this algorithm have been validated with a positive predictive value (PPV) above 90% for the diagnosis of IE in the Danish registries [15, 16]. See Supplemental Table 1 for ICD-, procedure- and ATC-codes used in this study.
Design of echocardiography flowchart
Based on the crude estimated IE prevalence, each streptococcal species was assigned to a risk group: low (< 3%), moderate (3–10%), high (10–30%), and very high (> 30%). After grouping the streptococcal species in risk groups, the IE prevalence was further assessed in subgroups according to number of positive blood culture bottles and presence of conventional IE risk factors (prosthetic valve, previous IE, native valve disease and cardiac device) [17, 18]. From these subgroups we decided to use the following cut-offs for the proposed use of TTE and TOE: (i) IE prevalence > 10%, TTE and are recommended (ii) IE prevalence of 3–10%, TTE is recommended (iii) IE prevalence < 3%, “wait & see” is recommended, meaning that no initial echocardiography is recommended unless there is a strong clinical suspicion of IE.
Statistics
Baseline data were presented for the four streptococcal risk groups. Categorical data were expressed as numbers and percentage (%), while continuous variables were presented as mean ± standard deviation (SD). Estimated prevalence of IE was calculated as BSI cases with concomitant IE diagnosis divided by the total number of BSI cases in the total cohort and in the different streptococcal species groups, respectively. The IE prevalence estimate was presented with a 95% confidence interval (CI). A multivariable logistic regression analysis with the outcome IE diagnosis in BSIs with different streptococcal species, adjusted for age, sex, ≥3 positive blood culture bottles, native valve disease, prosthetic valve, previous IE, and cardiac device, was carried out with S. pneumoniae as a reference species. Results were presented as odds ratio (OR) with 95% CI. The IE prevalence estimate of every step in the flowchart was calculated as cases with an IE diagnosis divided by the total number of BSI cases in each subgroup, with < or ≥ 3 positive blood culture bottles, and presence vs. absence of an IE risk factor. IE prevalence estimates were presented with a 95% confidence interval (CI). All statistical analyses were performed using the SAS statistical software, version 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
Patient inclusion and characteristics
From a total of 7122 streptococcal BSI cases we identified 6506 eligible cases with monospecies streptococcal BSIs in 6224 unique patients, of which 236 patients had more than one BSI case with a median of 332 days [IQR 102–869] between the first and the second episode. After excluding rare species (causing < 0.5% of BSIs) we included 6393 cases with monospecies streptococcal BSIs of which 451 were diagnosed with IE (7.1%) (Fig. 1). Based on the IE prevalence streptococcal species were classified as low-risk, moderate-risk, high-risk and very high-risk streptococci as described in the main study [9]. There were 3230 BSI cases (51%) in the low-risk group, 2106 BSI cases (33%) in the moderate-risk group, 556 BSI cases (9%) in the high-risk group, and 501 BSI cases (8%) in the very high-risk group (Fig. 1). In the total cohort the mean age was 68.1 years (SD 16.2) and 52.8% were men. Baseline characteristics according to risk groups are shown in Table 1. Cases in the very high-risk streptococci group were older and had the highest rate of native valve disease (13.2%), prosthetic valve (12.4%), previous IE (4.4%), and cardiac device (9.2%) (Table 1).
Fig. 1.
Patient inclusion. The figure illustrates a flowchart of patient selection. A total of 7122 cases of monospecies streptococcal BSIs were identified. Classification of species identification was unavailable in 279 cases. From the remaining 6843 cases, 65 cases had an invalid civil registration number, 272 cases were below 18 years of age, and 113 cases were infected with rare streptococcal species. BSI, bloodstream infection. Green: low-risk species (IE prevalence < 3%), yellow: moderate-risk species (IE prevalence 3–10%), orange: high-risk species (IE prevalence 10–30%), red: very high-risk species (IE prevalence > 30%)
Table 1.
Baseline characteristics
| Low-risk Streptococci (n = 3230) |
Moderate-risk streptococci (n = 2106) |
High-risk streptococci (n = 556) |
Very high-risk streptococci (n = 501) |
All BSIs (N = 6393) |
|
|---|---|---|---|---|---|
| Demographics | |||||
| Age, mean (SD) | 66.8 (16.5) | 69.4 (15.6) | 67.0 (17.1) | 72.2 (14.2) | 68.1 (16.2) |
| Male, n (%) | 1543 (47.8) | 1204 (57.2) | 325 (58.5) | 301 (60.1) | 3373 (52.8) |
| Comorbidities a | |||||
| Native valve disease b, n (%) | 97 (3.0) | 106 (5.0) | 38 (6.8) | 66 (13.2) | 307 (4.8) |
| Prosthetic valve, n (%) | 47 (1.5) | 61 (2.9) | 28 (5.0) | 62 (12.4) | 198 (3.1) |
| Previous IE, n (%) | 23 (0.7) | 34 (1.6) | 12 (2.2) | 22 (4.4) | 91 (1.4) |
| Cardiac device c, n (%) | 120 (3.7) | 101 (4.8) | 26 (4.7) | 46 (9.2) | 293 (4.6) |
| IHD, n (%) | 478 (14.8) | 428 (20.3) | 128 (23.0) | 138 (27.5) | 1172 (18.3) |
| CHF, n (%) | 365 (11.3) | 347 (16.5) | 89 (16.0) | 123 (24.6) | 924 (14.5) |
| Cancer, n (%) | 787 (24.4) | 671 (31.9) | 162 (29.1) | 130 (25.9) | 1750 (27.4) |
| COPD, n (%) | 612 (18.9) | 280 (13.3) | 105 (18.9) | 86 (17.2) | 1083 (16.9) |
| DM, n (%) | 386 (12.0) | 372 (17.7) | 84 (15.1) | 101 (20.2) | 943 (14.8) |
| Renal disease, n (%) | 230 (7.1) | 209 (9.9) | 64 (11.5) | 57 (11.4) | 560 (8.8) |
| Renal dialysis, n (%) | 44 (1.4) | 40 (1.9) | 13 (2.3) | 15 (3.0) | 112 (1.8) |
BSI Bloodstream infection, CHF Congestive heart failure, COPD Chronic obstructive pulmonary disease, DM Diabetes mellitus, IE Infective endocarditis, IHD Ischemic heart disease
a medical history prior to IE, b Native valve disease without prosthetic valve, c cardiac implantable electronic device
Adjusted risk of infective endocarditis
Figure 2 shows the crude prevalence of IE according to streptococcal species and the multivariable logistic regression adjusted for age, sex, and IE risk factors (≥ 3 positive blood culture bottles, native valve disease, prosthetic valve, previous IE and cardiac device). In the adjusted analysis including a slightly smaller cohort than in the main study, the overall risk pattern remained stable with progressively higher associated risk of IE in the species with the higher IE prevalence (Fig. 2).
Fig. 2.
Prevalence and adjusted risk of IE. The figure illustrates the IE prevalence in different streptococcal species. In addition, a multivariable logistic regression analysis of the IE risk, adjusted for age, sex, ≥3 positive blood culture bottles, and risk factors, is presented. S. pneumoniae BSI is set as a reference. The results are presented as OR (95% CI). The figure is partly adapted from the main study [9]. .a adjusted for age, sex, ≥3 positive blood culture bottles, native valve disease, prosthetic valve, previous IE, and cardiac device. b The exact number cannot be presented due to microdata. BSI, bloodstream infection; CI confidence interval; IE, infective endocarditis; OR, odds ratio. Green: low-risk species (IE prevalence < 3%), yellow: moderate-risk species (IE prevalence 3–10%), orange: high-risk species (IE prevalence 10–30%), red: very high-risk species (IE prevalence > 30%)
Endocarditis prevalence according to species, number of positive blood culture bottles, and risk factors
The IE prevalence was calculated for each streptococcal risk group and is presented relative to the number of positive blood culture bottles, and IE risk factors (Table 2). Low-risk streptococci (S. pneumoniae, S. pyogenes, and S. intermedius) had an IE prevalence of 0.5–1.5%, unless they had ≥3 positive blood culture bottles and at least one further risk factor in which case IE prevalence was 6.9% [95% CI: 3.4–12.3%]. Moderate-risk streptococci (S. agalactiae, S. anginosus, S. constellatus, S. dysgalactiae, S. salivarius, and S. thermophilus) had an IE prevalence of 1.5% [95% CI: 0.9–2.4%] if they neither had a risk factor nor ≥3 positive blood culture bottles, but an IE prevalence of 3–10% if they had either ≥3 positive blood culture bottles (IE prevalence 9.6% [95% CI: 7.5–12.1%]) or a risk factor (IE prevalence 8.7% [95% CI: 4.4–15.1%]). Moderate-risk streptococci presenting with both ≥3 positive blood culture bottles and a risk factor had an IE prevalence of 31.1% [95% CI: 23.3–39.7%]. High-risk streptococci (S. mitis/oralis, S. parasanguinis, and G. adiacens) had an IE prevalence of 3.6% [95% CI: 1.9–6.0%]) if they neither had a risk factor nor ≥3 positive blood culture bottles, but an IE prevalence of 14.0% [95% CI: 5.3–27.9%] if they presented a risk factor and < 3 positive blood culture bottles and an IE prevalence of 48.4% [95% CI: 40.4–56.5%] if they had ≥3 positive blood culture bottles. Finally, very high-risk streptococci (S. gordonii, S. gallolyticus (formerly S. bovis), S. mutans, and S. sanguinis) had a very high baseline IE prevalence of 35.7% [95% CI: 31.5–40.1%] (Table 2).
Table 2.
IE prevalence for steps in the flowchart
| Number of BSIs | Number of IE cases | IE prevalence with [95% CI] | |
|---|---|---|---|
| Low-risk species, baseline | 3230 | 41 | 1.3% [0.9–1.7%] |
| < 3 positive BC bottles | 1500 | 7 | 0.5% [0.2–1.0%] |
| ≥ 3 positive BC bottles without risk factors | 1585 | 24 | 1.5% [1.0–2.2%] |
| ≥ 3 positive BC bottles with a risk factor | 145 | 10 | 6.9% [3.4–12.3%] |
| Moderate-risk species, baseline | 2106 | 136 | 6.5% [5.4–7.6%] |
| < 3 positive BC bottles without risk factors | 1163 | 18 | 1.5% [0.9–2.4%] |
| < 3 positive BC bottles with a risk factor | 126 | 11 | 8.7% [4.4–15.1%] |
| ≥ 3 positive BC bottles without risk factors | 685 | 66 | 9.6% [7.5–12.1%] |
| ≥ 3 positive BC bottles with a risk factor | 132 | 41 | 31.1% [23.3–39.7%] |
| High-risk species, baseline | 556 | 95 | 17.1% [14.0–20.5%] |
| < 3 positive BC bottles without risk factors | 356 | 13 | 3.6% [1.9–6.0%] |
| < 3 positive BC bottles with a risk factor | 43 | 6 | 14.0% [5.3–27.9%] |
| ≥ 3 positive BC bottles | 157 | 76 | 48.4% [40.4–56.5%] |
| Very high-risk species, baseline | 501 | 179 | 35.7% [31.5–40.1%] |
BC Blood culture, BSI Bloodstream infection, CI Confidence interval, IE Infective endocarditis
Risk factors: native valve disease, prosthetic valve, previous IE or cardiac device
Proposed flowchart for echocardiography in streptococcal bacteraemia
Based on the estimated IE prevalence in BSIs with different streptococcal species and taking the number of positive blood culture bottles and IE risk factors into account we designed a flowchart for the use of TTE and TOE (Fig. 3). Using the specified IE prevalence cut-offs, we propose the following strategy: “wait & see” (IE prevalence < 3%), TTE (IE prevalence 3–10%), and TTE plus TOE (IE prevalence > 10%). In this way, low-risk streptococci are directed to “wait & see”, unless they have ≥3 positive blood culture bottles and an IE risk factor in which case they are led to TTE. Moderate-risk streptococci with < 3 positive blood culture bottles and no risk factors are guided to “wait & see”, whereas a TTE is recommended if they have either ≥3 positive blood culture bottles or a risk factor. However, moderate-risk streptococci presenting with both ≥3 positive blood culture bottles and a risk factor are recommended a TTE plus TOE. High-risk streptococci are recommended a TTE if they neither have a risk factor nor ≥3 positive blood culture bottles, but a TTE plus TOE if they have either ≥3 positive blood culture bottles or a risk factor. Finally, very high-risk streptococci are recommended a TTE plus TOE due to a very high baseline IE prevalence.
Fig. 3.
Echocardiography of streptococcal bloodstream infections. The figure shows a flowchart for the proposed use of echocardiography in patients with streptococcal bloodstream infections, based on streptococcal species, number of positive blood culture bottles, and presence of a risk factor. IE, infective endocarditis; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography
Discussion
Based on estimated IE prevalence, this study proposes a flowchart for the use of echocardiography in patients with BSIs caused by different streptococcal species. The main findings were: (i) BSI cases with a low-risk streptococcus (S. pneumoniae, S. pyogenes or S. intermedius) are not initially being recommended an echocardiography, unless they have ≥3 positive blood culture bottles and presence of an IE risk factor (ii) BSI cases with a very high-risk streptococcus (S. gordonii, S. gallolyticus, S. mutans, and S. sanguinis) or cases with ≥3 positive blood culture bottles with a high-risk streptococcus (S. mitis/oralis, S. parasanguinis or G. adiacens) are recommended to a TTE plus TOE.
To evaluate the possible clinical implications of these findings it is relevant to discuss the current clinical guidelines deciding when to perform TTE and/or TOE in patients with streptococcal BSIs. Neither IE guidelines from the European Society of Cardiology (ESC) nor the American Heart Association (AHA), are specifying anything regarding differentiation of work-up in patients with BSI due to different streptococcal species [10, 11]. However, in the diagnostic criteria for IE, which are based on the modified Duke criteria, BSIs with viridans streptococci and S. bovis are major diagnostic criteria [10, 19]. It is concerning that the term viridans streptococci covers all species in the S. anginosus group, S. mitis group, S. mutans group, and S. salivarius group without any distinction between specific species [20]. It is now evident, that different streptococcal species within the so called viridans streptococci have different IE prevalence, ranging from 4.8% in S. anginosus to 47.9% in S. mutans [9]. Therefore, it is highly relevant to differentiate the work-up in patients with streptococcal BSIs with different streptococcal species based on the associated risk of IE. To confront this problem, Sunnerhagen et al. created the HANDOC score based on 339 non-β-haemolytic streptococcal BSI cases and 26 cases of IE [12]. The score is aimed to guide the use of echocardiography by evaluating six factors: Heart murmur or valvular disease, Aetiology, Number of cultures, Duration of symptoms, Only one species, and Community acquisition. Despite the fact, that the score showed a high sensitivity in an external validation [21], the study was limited by only including few IE cases, not including all the different streptococcal species and not differentiating between when to perform TTE or TOE. Surprisingly, the authors only found 4 cases of IE in 102 S. mitis group BSIs in sharp contrast to most other studies finding S. mitis to cause the majority of IE cases in streptococcal BSIs [9, 22, 23]. Further, the authors suggest a reduction in the calculated score when patients are infected with S. anginosus BSIs, since they did not find any IE cases in 105 BSIs with S. anginosus [12]. This finding is not in line with recent findings in a much larger cohort, where the IE prevalence for S. anginosus BSIs was almost 5% (21 of 431) [9].
With nearly 6400 streptococcal BSI cases, we had sufficient numbers to evaluate the prevalence of IE on species level and stratify the species according to the prevalence of IE into low, moderate, high, and very high risk of IE. The overall estimated IE prevalence in our cohort (7.1%) was not markedly different from the one found in non-β-haemolytic streptococcal BSI (7.7%) and mixed streptococcal BSI (10.6%) [12, 24]. In addition, using the information from earlier studies of IE risk factors such as native valve disease, prosthetic valve, previous IE, and cardiac device we were able to incorporate these details in the flowchart [17, 18]. To determine the IE prevalence cut-offs for our proposed use of echocardiography we combined clinical experience with knowledge from earlier studies on typical IE bacteria to reach a consensus decision. Previous studies on S. aureus and E. faecalis IE have recommended TTE and TOE based on IE prevalence from 10 to 25% [5–7]. We decided to use an IE prevalence of 10% as cut-off for TOE to accommodate the fact that our numbers are likely to be conservative estimates lacking information on BSI cases where no echocardiography was performed (data not available). To select the IE prevalence limit for an expectant strategy (“wait & see”) we considered the prevalence of IE in S. aureus and E. faecalis BSI cases without any risk factors (3.4–5%) from earlier studies [6, 7]. Since these patients in low to moderate risk of IE are often still recommended a TTE we chose a lower limit of < 3% for the expectant strategy. In our study the IE prevalence in the subgroups of BSI cases leading to a “wait & see” strategy was well below this limit. It is adamant to underscore that the flowchart is thought as an additional tool to help the clinician and that the overall clinical assessment of the patient is still crucial. Therefore, clinical findings such as persistent or recurrent bacteraemia, signs of metastatic infection (e.g. embolic event) or acute heart failure should of course lead to echocardiography and work up for IE no matter the outcome of the flowchart.
Limitations
The flowchart is created on retrospective data from a partly register-based setup, which naturally introduces limitations. Firstly, the diagnosis of IE was based on ICD-10 discharge codes with the inherent risk of misclassification bias. However, the applied method using ICD-10 codes in the Danish registries has been validated with a positive predictive value for the diagnosis of IE of 90% [15]. Since the negative predictive value of the IE diagnosis in the Danish registries has not been investigated, we cannot accurately estimate the amount of overlooked IE patients that were misclassified (false negatives) by not receiving an ICD-10 IE diagnosis. Secondly, since data on TTE and TOE are not available, the flowchart was created retrospectively without knowledge of the use of echocardiography in the different groups. Since echocardiography plays a central role in diagnosing IE it would have been relevant to know if some species were less often examined with echocardiography thereby increasing the probability of ascertainment bias and missed IE cases. Having that in mind, the IE prevalence should be interpreted as conservative estimates. At the same time, the missing data on echocardiograms introduces a risk of circular deduction where the species more typically examined by echocardiography also becomes the species where IE is diagnosed most often. In other words that the current clinical selection of patients for echocardiography are already performed in a manner parallel to the suggested flow chart without collective consciousness of the specific selection process. In this way the suggested flowchart may just be the first actual description of the performed clinical practice applied by IE experts. The only way to answer this question is to perform a prospective screening study with systematic echocardiography in all patients with streptococcal BSI. Thirdly, all positive BC bottles occurring within 14 days of the first positive BC were considered part of same BSI episode without the possibility to distinguish persistent bacteraemia from several positive BCs obtained in a single initial BC sampling. Fourth, the present study was performed in a specific geographical setting in Scandinavia, which may not represent the prevalence of IE according to streptococcal species in other regions of the world. Finally, it is important to emphasize that the proposed flowchart should not stand alone and the clinical evaluation of the patient is still central in the decision making as stated in the international guidelines [10, 11].
Conclusion
In addition to the clinical picture, this flowchart based on streptococcal species, number of positive blood culture bottles, and risk factors, can help guide the decision to perform echocardiography in patients with streptococcal bloodstream infections. Since echocardiography results are not available the flowchart should be further validated in a clinical prospective setup with use of systematic echocardiography and in other geographical settings.
Supplementary Information
Additional file 1: Table S1. ICD-, procedure- and ATC-codes.
Acknowledgements
Not applicable.
Abbreviations
- AHA
American Heart Association
- ATC
Anatomical Therapeutic Chemical
- BC
Blood culture
- BSI
Bloodstream infection
- CHF
Congestive heart failure
- CI
Confidence interval
- COPD
Chronic obstructive pulmonary disease
- DM
Diabetes mellitus
- E. faecalis
Enterococcus faecalis
- ESC
European Society of Cardiology
- G. adiacens
Granulicatella adiacens
- ICD
International Classification of Diseases
- IE
Infective endocarditis
- IHD
Ischemic heart disease
- NOMESCO
Nordic Medico-Statistical Committee
- OR
Odds ratio
- PPV
Positive predictive value
- S. aureus
Staphylococcus aureus
- SD
Standard deviation
- TOE
Transoesophageal echocardiography
- TTE
Transthoracic echocardiography
Authors’ contributions
SCH, NEB and AD: Design of the project, analysis of data, draft of the manuscript. MA and JB: Design of the project, data extraction, critical revision of data, reviewing and editing the manuscript. LØ, EF, LBO, TKL, GG and CTP: Design of the project, critical revision of data, reviewing and editing the manuscript. All authors have read and approved the final manuscript.
Funding
This work was supported by the University Hospital of Copenhagen Herlev and Gentofte (Research Council and Department of Cardiology), Helsefonden, and Director Jacob Madsen and wife Olga Madsen’s research foundation. The funders of the study were not involved in the study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit the paper for publication.
Availability of data and materials
All supportive data are available within the article and its supplementary files.
Declarations
Ethics approval and consent to participate
The study was performed as a retrospective administrative registry study, where all data were anonymised before use. All data used for this study are held by Statistics Denmark, which also has the administrative rights to the data and encrypts the identification number likewise in all datasets. In retrospective register studies in Denmark, ethics approval and individual consent is not required and all methods were performed in accordance with the relevant guidelines and regulations [13]. The data handling and storage in the project has been approved by the Danish Data Protection Agency (approval number 2007–58-015/GEH-2014-018 I-Suite number 02736).
Consent for publication
Not applicable.
Competing interests
SCH has nothing to declare.
NEB has nothing to declare.
LØ has nothing to declare.
MA has nothing to declare.
EF has nothing to declare.
JB has nothing to declare.
LBO has nothing to declare.
TKL has nothing to declare.
GG has nothing to declare.
CTP has nothing to declare.
AD reports grants from The Lundbeck Foundation and the European Society of Cardiology unrelated to this study.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, Popescu BA, Prendergast B, Tornos P, Sadeghpour A, Oliver L, Vaskelyte JJ, Sow R, Axler O, Maggioni AP, Lancellotti P, EURO-ENDO Investigators. Gale CP, Beleslin B, Budaj A, Chioncel O, Dagres N, Danchin N, Emberson J, Erlinge D, Glikson M, Gray A, Kayikcioglu M, Maggioni AP, Nagy VK, Nedoshivin A, Petronio AS, Roos-Hesselink J, Wallentin L, Zeymer U, Habib G, Lancellotti P, Cosyns B, Donal E, Erba P, Iung B, Maggioni AP, Popescu BA, Prendergast B, Tornos P, Andarala M, Berle C, Brunel-Lebecq A, Fiorucci E, Laroche C, Missiamenou V, Taylor C, Ali Tatar-Chentir NN, al-Mallah M, Astrom Aneq M, Athanassopoulos G, Badano LP, Benyoussef S, Calderon Aranda E, Cardim NM, Chan KL, Cosyns B, Cruz I, Edvardsen T, Goliasch G, Habib G, Hagendorff A, Hristova K, Iung B, Kamp O, Kang DH, Kong W, Matskeplishvili S, Meshaal M, Mirocevic M, Neskovic AN, Pazdernik M, Plonska-Gosciniak E, Popescu BA, Prendergast B, Raissouni M, Ronderos R, Sade LE, Sadeghpour A, Sambola A, Sengupta S, Separovic-Hanzevacki J, Takeuchi M, Tucay E, Tude Rodrigues AC, Varga A, Vaskelyte J, Yamagata K, Yiangou K, Zaky H, Granada I, Mahia M, Ressi S, Nacinovich F, Iribarren A, Fernandez Oses P, Avegliano G, Filipini E, Obregon R, Bangher M, Dho J, Cartasegna L, Plastino ML, Novas V, Shigel C, Reyes G, de Santos M, Gastaldello N, Granillo Fernandez M, Potito M, Streitenberger G, Velazco P, Casabé JH, Cortes C, Guevara E, Salmo F, Seijo M, Weidinger F, Heger M, Brooks R, Stöllberger C, Ho CY, Perschy L, Puskas L, Binder C, Rosenhek R, Schneider M, Winter MP, Hoffer E, Melissopoulou M, Lecoq E, Legrand D, Jacquet S, Massoz M, Pierard L, Marchetta S, Dulgheru R, Emal CD’, Oury C, Droogmans S, Kerkhove D, Plein D, Soens L, Weytjens C, Motoc A, Roosens B, Lemoine I, Rodrigus I, Paelinck B, Amsel B, Unger P, Konopnicki D, Beauloye C, Pasquet A, Vanoverschelde JL, Pierard S, Vancraeynest D, Sinnaeve F, Andrade JL, Staszko K, Dos Santos Monteiro R, Miglioranza MH, Shuha DL, Alcantara M, Cravo V, Fazzio L, Felix A, Iso M, Musa C, Siciliano AP, Villaca Filho F, Rodrigues A, Vilela F, Braga J, Silva R, Rodrigues D, Silva L, Morhy S, Fischer C, Silva R, Vieira M, Afonso T, Abreu J, Falcao SN, Moises VA, Gouvea A, Mancuso FJ, Souza AC, Silva CY, João G, Abboud CS, Bellio de Mattos Barretto R, Ramos A, Arnoni R, Assef JE, Della Togna DJ, le Bihan D, Miglioli L, Romero Oliveira AP, Tadeu Magro Kroll R, Cortez D, Gelape CL, Peirira Nunes MC, de Abreu Ferrari TC, Hay K, le V, Page M, Poulin F, Sauve C, Serri K, Mercure C, Beaudoin J, Pibarot P, Sebag IA, Rudski LG, Ricafort G, Barsic B, Krajinovic V, Vargovic M, Lovric D, Reskovic-Luksic V, Vincelj J, Jaksic Jurinjak S, Yiannikourides V, Ioannides M, Pofaides C, Masoura V, Pudich J, Linhart A, Siranec M, Marek J, Blechova K, Kamenik M, Pelouch R, Coufal Z, Mikulica M, Griva M, Jancova E, Mikulcova M, Taborsky M, Precek J, Jecmenova M, Latal J, Widimsky J, Butta T, Machacek S, Vancata R, Spinar J, Holicka M, Pow Chon Long F, Anzules N, Bajana Carpio A, Largacha G, Penaherrera E, Moreira D, Mahfouz E, Elsafty E, Soliman A, Zayed Y, Aboulenein J, Abdel-Hay M, Almaghraby A, Abdelnaby M, Ahmed M, Hammad B, Saleh Y, Zahran H, Elgebaly O, Saad A, Ali M, Zeid A, el Sharkawy R, al Kholy A, Doss R, Osama D, Rizk H, Elmogy A, Mishriky M, Assayag P, el Hatimi S, Hubert S, Casalta JP, Gouriet F, Arregle F, Cammilleri S, Tessonnier L, Riberi A, Botelho-Nevers E, Gagneux-Brunon A, Pierrard R, Tulane C, Campisi S, Fuzellier JF, Detoc M, Mehalla T, Boutoille D, Lecompte AS, Lefebvre M, Pattier S, al Habash O, Asseray-Madani N, Biron C, Brochard J, Caillon J, Cueff C, le Tourneau T, Lecomte R, Magali Michel MM, Orain J, Delarue S, le Bras M, Faucher JF, Aboyans V, Beeharry A, Durox H, Lacoste M, Magne J, Mohty D, David A, Pradel V, Sierra V, Neykova A, Bettayeb B, Elkentaoui S, Tzvetkov B, Landry G, Strady C, Ainine K, Baumard S, Brasselet C, Tassigny C, Valente-Pires V, Lefranc M, Hoen B, Lefevre B, Curlier E, Callier C, Fourcade N, Jobic Y, Ansard S, le Berre R, le Ven F, Pouliquen MC, Prat G, le Roux P, Bouchart F, Savoure A, Alarcon C, Chapuzet C, Gueit I, Tribouilloy C, Bohbot Y, Peugnet F, Gun M, Duval X, Lescure X, Ilic-Habensus E, Sadoul N, Selton-Suty C, Alla F, Goehringer F, Huttin O, Chevalier E, Garcia R, le Marcis V, Tattevin P, Flecher E, Revest M, Chirouze C, Bouiller K, Hustache-Mathieu L, Klopfenstein T, Moreau J, Fournier D, Brunel AS, Lim P, Oliver L, Ternacle J, Moussafeur A, Chavanet P, Piroth L, Salmon-Rousseau A, Buisson M, Mahy S, Martins C, Gohier S, Axler O, Baumann F, Lebras S, Piper C, Guckel D, Börgermann J, Horstkotte D, Winkelmann E, Brockmeier B, Grey D, Nickenig G, Schueler R, Öztürk C, Stöhr E, Hamm C, Walther T, Brandt R, Frühauf AC, Hartung CT, Hellner C, Wild C, Becker M, Hamada S, Kaestner W, Stangl K, Knebel F, Baldenhofer G, Brecht A, Dreger H, Isner C, Pfafflin F, Stegemann M, Zahn R, Fraiture B, Kilkowski C, Karcher AK, Klinger S, Tolksdorf H, Tousoulis D, Aggeli C, Sideris S, Venieri E, Sarri G, Tsiapras D, Armenis I, Koutsiari A, Floros G, Grassos C, Dragasis S, Rallidis L, Varlamos C, Michalis L, Naka K, Bechlioulis A, Kotsia A, Lakkas L, Pappas K, Papadopoulos C, Kiokas S, Lioni A, Misailidou S, Barbetseas J, Bonou M, Kapelios C, Tomprou I, Zerva K, Manolis A, Hamodraka E, Athanasiou D, Haralambidis G, Samaras H, Poulimenos L, Nagy A, Bartykowszki A, Gara E, Mungulmare K, Kasliwal R, Bansal M, Ranjan S, Bhan A, Kyavar M, Maleki M, Noohi Bezanjani F, Alizadehasl A, Boudagh S, Ghavidel A, Moradnejad P, Pasha HR, Ghadrdoost B, Gilon D, Strahilevitz J, Wanounou M, Israel S, d'Agostino C, Colonna P, de Michele L, Fumarola F, Stante M, Marchionni N, Scheggi V, Alterini B, del Pace S, Stefano P, Sparano C, Ruozi N, Tenaglia R, Muraru D, Limbruno U, Cresti A, Baratta P, Solari M, Giannattasio C, Moreo A, de Chiara B, Lopez Montero B, Musca F, Orcese CA, Panzeri F, Spano F, Russo CF, Alfieri O, de Bonis M, Chiappetta S, del Forno B, Ripa M, Scarpellini P, Tassan Din C, Castiglioni B, Pasciuta R, Carletti S, Ferrara D, Guffanti M, Iaci G, Lapenna E, Nisi T, Oltolini C, Busnardo E, Pajoro U, Agricola E, Meneghin R, Schiavi D, Piscione F, Citro R, Benvenga RM, Greco L, Soriente L, Radano I, Prota C, Bellino M, di Vece D, Santini F, Salsano A, Olivieri GM, Turrini F, Messora R, Tondi S, Olaru A, Agnoletto V, Grassi L, Leonardi C, Sansoni S, del Ponte S, Actis Dato GM, de Martino A, Ohte N, Kikuchi S, Wakami K, Aonuma K, Seo Y, Ishizu T, Machino-Ohtsuka T, Yamamoto M, Iida N, Nakajima H, Nakagawa Y, Izumi C, Amano M, Miyake M, Takahashi K, Shiojima I, Miyasaka Y, Maeba H, Suwa Y, Taniguchi N, Tsujimoto S, Kitai T, Ota M, Yuda S, Sasaki S, Hagiwara N, Yamazaki K, Ashihara K, Arai K, Saitou C, Saitou S, Suzuki G, Shibata Y, Watanabe N, Nishino S, Ashikaga K, Kuriyama N, Mahara K, Okubo T, Fujimaki H, Shitan H, Yamamoto H, Abe K, Terada M, Takanashi S, Sata M, Yamada H, Kusunose K, Saijo Y, Seno H, Yuichiro O, Onishi T, Sera F, Nakatani S, Mizuno H, Sengoku K, Park SW, Eun Kyoung K, Ga Yeon L, Hwang JW, Jin-Oh C, Park SJ, Sang-Chol L, Sung-A C, Jang SY, Heo R, Lee S, Song JM, Jung E, Plisiene J, Dambrauskaite A, Gruodyte G, Jonkaitiene R, Mizariene V, Atkocaityte J, Zvirblyte R, Sow R, Codreanu A, Staub T, Michaux C, de la Vega ECL, Jacobs-Orazi L, Mallia Azzopardi C, Xuereb RG, Piscopo T, Farrugia J, Fenech M, Pllaha E, Vella C, Borg D, Casha R, Grib L, Raevschi E, Grejdieru A, Kravcenco D, Prisacari E, Samohvalov E, Samohvalov S, Sceglova N, Panfile E, Cardaniuc L, Corcea V, Feodorovici A, Gaina V, Girbu L, Jimbei P, Balan G, Cardaniuc I, Benesco I, Marian V, Sumarga N, Bozovic B, Bulatovic N, Lakovic P, Music L, Budde R, Wahadat A, Gamela T, Meijers T, van Melle JP, Deursen VM, Crijns HJ, Bekkers SC, Cheriex EC, Gilbers M, Kietselaer BL, Knackstedt C, Lorusso R, Schalla S, Streukens SA, Chamuleau S, Cramer MJ, Teske A, van der Spoel T, Wind A, Lokhorst J, Liesbek O, van Heusden H, Tanis W, van der Bilt I, Vriend J, de Lange-van Bruggen H, Karijodikoro E, Riezebos R, van Dongen E, Schoep J, Stolk V, Offstad JT, Beitnes JO, Helle-Valle T, Skulstad H, Skardal R, Qamar N, Furnaz S, Ahmed B, Butt MH, Khanzada MF, Saghir T, Wahid A, Hryniewiecki T, Szymanski P, Marzec K, Misztal-Ogonowska M, Kosmala W, Przewlocka-Kosmala M, Rojek A, Woznicka K, Zachwyc J, Lisowska A, Kaminska M, Kasprzak JD, Kowalczyk E, Strzecka DF, Wejner-Mik P, Trabulo M, Freitas P, Ranchordas S, Rodrigues G, Pinto P, Queiros C, Azevedo J, Marques L, Seabra D, Branco L, Abreu J, Cruz M, Galrinho A, Moreira R, Rio P, Timoteo AT, Selas M, Carmelo V, Duque Neves B, Pereira H, Guerra A, Marques A, Pintassilgo I, Tomescu MC, Trofenciuc NM, Andor M, Bordejevic A, Branea HS, Caruntu F, Velcean LA, Mavrea A, Onel MF, Parvanescu T, Pop D, Pop-Moldovan AL, Puticiu MI, Cirin L, Citu IM, Cotoraci CA, Darabantiu D, Farcas R, Marincu I, Ionac A, Cozma D, Mornos C, Goanta F, Popescu I, Beyer R, Mada R, Rancea R, Tomoaia R, Rosianu H, Stanescu C, Kobalava Z, Karaulova J, Kotova E, Milto A, Pisaryuk A, Povalyaev N, Sorokina M, Alrahimi J, Elshiekh A, Jamiel A, Ahmed A, Attia N, Putnikovic B, Dimic A, Ivanovic B, Matic S, Trifunovic D, Petrovic J, Kosevic D, Stojanovic I, Petrovic I, Dabic P, Milojevic P, Srdanovic I, Susak S, Velicki L, Vulin A, Kovacevic M, Redzek A, Stefanovic M, Yeo TC, Kong WKF, Poh KK, Vilacosta I, Ferrera C, Olmos C, Abd el- Nasser M, Calvo Iglesias F, Blanco-Gonzalez E, Bravo Amaro M, Lopez-Rodriguez E, Lugo Adan J, Germinas AN, Pazos-Lopez P, Pereira Loureiro M, Perez MT, Raposeiras-Roubin S, Rasheed Yas S, Suarez-Varela MM, Vasallo Vidal F, Garcia-Dorado D, Fernandez-Hidalgo N, Gonzalez-Alujas T, Lozano J, Maisterra O, Pizzi N, Rios R, Bayes-Genis A, Pedro Botet L, Vallejo N, Llibre C, Mateu L, Nunez R, Quesada D, Berastegui E, Bosch Portell D, Aboal Vinas J, Albert Bertran X, Brugada Tarradellas R, Loma-Osorio Ricon P, Tiron de Llano C, Arnau MA, Bel A, Blanes M, Osa A, Anguita M, Carrasco F, Castillo JC, Zamorano JL, Moya Mur JL, Alvaro M, Fernandez-Golfin C, Monteagudo JM, Navas Elorza E, Farinas Alvarez MC, Aguero Balbin J, Zarauza J, Gutierrez-Diez JF, Arminanzas C, Arnaiz de las Revillas F, Arnaiz Garcia A, Cobo Belaustegui M, Fernandez Sampedro M, Gutierrez Cuadra M, Garcia Cuello L, Gonzalez Rico C, Rodriguez-Alvarez R, Goikoetxea J, Montejo M, Miro JM, Almela M, Ambrosioni J, Moreno A, Quintana E, Sandoval E, Tellez A, Tolosana JM, Vidal B, Falces C, Fuster D, Garcia-de-la-Maria C, Hernandez-Meneses M, Llopis J, Marco F, Ruiz-Zamora I, Bardaji Ruiz A, Sanz Girgas E, Garcia-Pardo G, Guillen Marzo M, Rodriguez Oviedo A, Villares Jimenez A, Abid L, Hammami R, Kammoun S, Mourali MS, Zghal FM, Ben Hlima M, Boudiche S, Ouali S, Zakhama L, Antit S, Slama I, Gulel O, Sahin M, Sade LE, Karacaglar E, Kucukoglu S, Cetinarslan O, Sinan UY, Canpolat U, Mutlu B, Atas H, Dervishova R, Ileri C, Alhashmi J, Tahir J, Zarger P, Baslib F, Woldman S, Menezes L, Primus C, Uppal R, Bvekerwa I, Chandrasekaran B, Kopanska A, Chambers J, Hancock J, Klein J, Rajani R, Ursi MP, Cannata S, Dworakowski R, Fife A, Breeze J, Browne-Morgan M, Gunning M, Streather S, Asch FM, Zemedkun M, Alyavi B, Uzokov J. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222–3232. doi: 10.1093/eurheartj/ehz620. [DOI] [PubMed] [Google Scholar]
- 2.Olmos C, Vilacosta I, Fernández-Pérez C, Bernal JL, Ferrera C, García-Arribas D, Pérez-García CN, San Román JA, Maroto L, Macaya C, Elola FJ. The evolving nature of infective endocarditis in Spain. J Am Coll Cardiol. 2017;70(22):2795–2804. doi: 10.1016/j.jacc.2017.10.005. [DOI] [PubMed] [Google Scholar]
- 3.Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, Hirsch GA, Mehta JL. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol. 2015;65(19):2070–2076. doi: 10.1016/j.jacc.2015.03.518. [DOI] [PubMed] [Google Scholar]
- 4.Erdem H, Puca E, Ruch Y, Santos L, Ghanem-Zoubi N, Argemi X, Hansmann Y, Guner R, Tonziello G, Mazzucotelli JP, Como N, Kose S, Batirel A, Inan A, Tulek N, Pekok AU, Khan EA, Iyisoy A, Meric-Koc M, Kaya-Kalem A, Martins PP, Hasanoglu I, Silva-Pinto A, Oztoprak N, Duro R, Almajid F, Dogan M, Dauby N, Gunst JD, Tekin R, Konopnicki D, Petrosillo N, Bozkurt I, Wadi J, Popescu C, Balkan II, Ozer-Balin S, Zupanc TL, Cascio A, Dumitru IM, Erdem A, Ersoz G, Tasbakan M, Ajamieh OA, Sirmatel F, Florescu S, Gulsun S, Ozkaya HD, Sari S, Tosun S, Avci M, Cag Y, Celebi G, Sagmak-Tartar A, Karakus S, Sener A, Dedej A, Oncu S, del Vecchio RF, Ozturk-Engin D, Agalar C. Portraying infective endocarditis: results of multinational ID-IRI study. Eur J Clin Microbiol Infect Dis. 2019;38(9):1753–1763. doi: 10.1007/s10096-019-03607-x. [DOI] [PubMed] [Google Scholar]
- 5.Østergaard L, Bruun NE, Voldstedlund M, Arpi M, Andersen CØ, Schønheyder HC, Lemming L, Rosenvinge F, Valeur N, Søgaard P, Andersen PS, Skov R, Chen M, Iversen K, Gill S, Lauridsen TK, Dahl A, Oestergaard LB, Povlsen JA, Moser C, Bundgaard H, Køber L, Fosbøl EL. Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study. Eur Heart J. 2019;40(39):3237–3244. doi: 10.1093/eurheartj/ehz327. [DOI] [PubMed] [Google Scholar]
- 6.Dahl A, Iversen K, Tonder N, Hoest N, Arpi M, Dalsgaard M, Chehri M, Soerensen LL, Fanoe S, Junge S, Hoest U, Valeur N, Lauridsen TK, Fosbol E, Hoi-Hansen T, Bruun NE. Prevalence of infective endocarditis in enterococcus faecalis bacteremia. J Am Coll Cardiol. 2019;74(2):193–201. doi: 10.1016/j.jacc.2019.04.059. [DOI] [PubMed] [Google Scholar]
- 7.Rasmussen RV, Høst U, Arpi M, Hassager C, Johansen HK, Korup E, et al. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography. Eur J Echocardiogr. 2011;12(6):414–420. doi: 10.1093/ejechocard/jer023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Dahl A, Lauridsen TK, Arpi M, Sørensen LL, Østergaard C, Sogaard P, Bruun NE. Risk factors of endocarditis in patients with enterococcus faecalis bacteremia: external validation of the NOVA score. Clin Infect Dis. 2016;63(6):771–775. doi: 10.1093/cid/ciw383. [DOI] [PubMed] [Google Scholar]
- 9.Chamat-Hedemand S, Dahl A, Østergaard L, Arpi M, Fosbøl E, Boel J, Oestergaard LB, Lauridsen TK, Gislason G, Torp-Pedersen C, Bruun NE. Prevalence of infective endocarditis in streptococcal bloodstream infections is dependent on streptococcal species. Circulation. 2020;142(8):720–730. doi: 10.1161/CIRCULATIONAHA.120.046723. [DOI] [PubMed] [Google Scholar]
- 10.Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Eur Heart J. 2015;36(44):3075–3128. doi: 10.1093/eurheartj/ehv319. [DOI] [PubMed] [Google Scholar]
- 11.Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and Management of Complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–1486. doi: 10.1161/CIR.0000000000000296. [DOI] [PubMed] [Google Scholar]
- 12.Sunnerhagen T, Törnell A, Vikbrant M, Nilson B, Rasmussen M. HANDOC: a Handy score to determine the need for echocardiography in non-β-hemolytic streptococcal bacteremia. Clin Infect Dis. 2018;66(5):693–698. doi: 10.1093/cid/cix880. [DOI] [PubMed] [Google Scholar]
- 13.Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi: 10.2147/CLEP.S91125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263–268. [PubMed] [Google Scholar]
- 15.Østergaard L, Adelborg K, Sundbøll J, Pedersen L, Loldrup Fosbøl E, Schmidt M. Positive predictive value of infective endocarditis in the Danish National Patient Registry: a validation study. Epidemiol Infect. 2018;146(15):1965–1967. doi: 10.1017/S0950268818001401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Sundbøll J, Adelborg K, Munch T, Frøslev T, Sørensen HT, Bøtker HE, Schmidt M. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open. 2016;6(11):e012832. doi: 10.1136/bmjopen-2016-012832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Østergaard L, Valeur N, Wang A, Bundgaard H, Aslam M, Gislason G, Torp-Pedersen C, Bruun NE, Søndergaard L, Køber L, Fosbøl EL. Incidence of infective endocarditis in patients considered at moderate risk. Eur Heart J. 2019;40(17):1355–1361. doi: 10.1093/eurheartj/ehy629. [DOI] [PubMed] [Google Scholar]
- 18.Østergaard L, Valeur N, Ihlemann N, Bundgaard H, Gislason G, Torp-Pedersen C, Bruun NE, Søndergaard L, Køber L, Fosbøl EL. Incidence of infective endocarditis among patients considered at high risk. Eur Heart J. 2018;39(7):623–629. doi: 10.1093/eurheartj/ehx682. [DOI] [PubMed] [Google Scholar]
- 19.Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–638. doi: 10.1086/313753. [DOI] [PubMed] [Google Scholar]
- 20.Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev. 2002;15(4):613–630. doi: 10.1128/CMR.15.4.613-630.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Sunnerhagen T, Andersen MH, Bruun NE, Bundgaard H, Iversen KK, Rasmussen M. External validation of the HANDOC score – high sensitivity to identify patients with non-beta-haemolytic streptococcal endocarditis. Infect Dis. 2019;0:1–4. doi: 10.1080/23744235.2019.1679388. [DOI] [PubMed] [Google Scholar]
- 22.Kim SL, Gordon SM, Shrestha NK. Distribution of streptococcal groups causing infective endocarditis: a descriptive study. Diagn Microbiol Infect Dis. 2018;91(3):269–272. doi: 10.1016/j.diagmicrobio.2018.02.015. [DOI] [PubMed] [Google Scholar]
- 23.Nilson B, Olaison L, Rasmussen M. Clinical presentation of infective endocarditis caused by different groups of non-beta haemolytic streptococci. Eur J Clin Microbiol Infect Dis. 2016;35(2):215–218. doi: 10.1007/s10096-015-2532-5. [DOI] [PubMed] [Google Scholar]
- 24.Andersen MH, Holle SLK, Klein CF, Bruun NE, Arpi M, Bundgaard H, Tønder N, Iversen KK. Risk for infective endocarditis in bacteremia with gram positive cocci. Infection. 2020;48(6):905–912. doi: 10.1007/s15010-020-01504-6. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional file 1: Table S1. ICD-, procedure- and ATC-codes.
Data Availability Statement
All supportive data are available within the article and its supplementary files.